India, Oct. 27 -- Shares of Aclaris Therapeutics, Inc. (ACRS) are falling 3 percent on Tuesday morning after the company announced positive Phase 1b proof-of-concept results for ATI-052 and pricing of an underwritten offering of about 7.9 million shares of its common stock at a price of $3.50 per share.
The company's stock is currently trading at $3.67, down 3.05 percent, over the previous close of $3.79 on the Nasdaq. It has traded between $2.1 and $6.6 in the past year.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....